AREV Life Sciences Global Corp. (AREVF)
OTCMKTS · Delayed Price · Currency is USD
0.0005
0.00 (0.00%)
At close: Dec 18, 2025
AREV Life Sciences Global Revenue
AREV Life Sciences Global had revenue of 7.21K CAD in the twelve months ending September 30, 2023, down -96.08% year-over-year. In the year 2022, AREV Life Sciences Global had annual revenue of 49.11K, down -80.74%.
Revenue (ttm)
7.21K CAD
Revenue Growth
-96.08%
P/S Ratio
2.98
Revenue / Employee
3.60K CAD
Employees
2
Market Cap
15.88K USD
Revenue Chart
* This company reports financials in CAD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 49.11K | -205.88K | -80.74% |
| Dec 31, 2021 | 255.00K | 64.42K | 33.80% |
| Dec 31, 2020 | 190.58K | -4.11K | -2.11% |
| Dec 31, 2019 | 194.69K | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| American Oncology Network | 1.76B |
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Vaxart | 148.20M |
| Elite Pharmaceuticals | 122.89M |
| Silence Therapeutics | 25.83M |
| OpGen | 9.00M |
| Stem Cell Authority | 3.33M |
AREV Life Sciences Global News
- 4 years ago - Kevin Phelps, CPA Appointed Chief Operating Officer of Arev Life Sciences Global Corporation & Warrant Offering - GlobeNewsWire
- 4 years ago - AREV Life Sciences Global Corporation announces engagement of TransBIOTech to facilitate preclinical therapeutic pipeline development - GlobeNewsWire
- 4 years ago - AREV Life Sciences Completes Lab and Fungi Fruiting Room Build - GlobeNewsWire
- 4 years ago - AREV Signs Definitive Collaborative Development Agreement with Voynich Biosciences and Invites Richard van Breemen PhD to SAB - GlobeNewsWire
- 4 years ago - AREV Announces Brian Cameron as Chief Financial Officer - GlobeNewsWire
- 4 years ago - Data Presented at the 11th IAS Conference on HIV Science Supports AREV's Development of SUS-TAINN™, a Ready-to-Use Therapeutic Food to Treat Global Malnutrition and Starvation - GlobeNewsWire
- 4 years ago - AREV Annual and Special General Meeting Results - GlobeNewsWire
- 4 years ago - AREV Expands Operations to Rochester New York Establishing Wholly Owned U.S. Subsidiary, AREV Life Sciences, Inc. - GlobeNewsWire